Italian Rx Price Cuts Are Brand Pharma’s Pain; Will They Even Be Generics’ Gain?
This article was originally published in The Pink Sheet Daily
Executive Summary
As Italy’s government turns the austerity screw, physicians will need to be convinced to adopt INN-based prescribing in order for sales to see a boost.
You may also be interested in...
The Year Ahead In Europe: More Price Cuts, More Austerity
Further austerity plans will be drawn up and drug price cuts implemented in Europe during 2012, as governments try to come to grips with their debts and with the eurozone currency crisis.
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
EMA Acts To Freeze GVK Drugs, Guard Against Shortages
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.